Literature DB >> 24980182

Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011.

N Dehamchia-Rehailia1, D Ursu, I Henry-Desailly, P Fardellone, J Paccou.   

Abstract

SUMMARY: The main goal was to assess the performance of the fracture liaison service (FLS) at Amiens University Hospital for 2 years. Osteoporosis medication was prescribed in 182 patients and 67.4 % were still taking treatment 18 months later. Secondary prevention of osteoporotic fractures has improved since the creation of the FLS.
INTRODUCTION: The main goal of the present study was to assess the performance and results of the FLS at Amiens University Hospital, France.
METHODS: This was an observational, single-center, ambispective study. All patients admitted to Amiens University Hospital between January 2010 and December 2011 for a low-trauma fracture (vertebral and non-vertebral fractures) were identified by a FLS nurse. Patients willing to enter the study were assessed for their osteoporosis risk factors, daily calcium intake, bone mineral density (BMD) by DXA, and clinical chemistry parameters. When indicated, the patients received a prescription for osteoporosis medication. The participation rate, type of osteoporosis medications, initiation rate, and osteoporosis treatment persistence 12 and 18 months later were assessed.
RESULTS: Of the 1,439 patients contacted, 872 were eligible for inclusion. A total of 335 patients (participation rate 38.4 %) were included in the study (mean age 63.3 years; 71.9 % female). All patients underwent BMD measurement, and more than 90 % of them were assessed for osteoporosis risk factors and daily calcium intake. Osteoporosis medication was prescribed in 182 (75.5 %) of the patients in whom it was indicated (n = 241). The main class of osteoporosis medications prescribed was bisphosphonates (83.5 %), and 74.1 and 67.4 % of treated patients were still taking treatment 12 and 18 months later, respectively. The main cause of treatment discontinuation was non-renewal of the prescription by the patient's general practitioner.
CONCLUSION: Secondary prevention of osteoporotic fractures in Amiens University Hospital has improved since the creation of the FLS, with encouragingly high treatment initiation and persistence rates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980182     DOI: 10.1007/s00198-014-2774-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

1.  Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates.

Authors:  S Ojeda-Bruno; A Naranjo; F Francisco-Hernández; C Erausquin; I Rúa-Figueroa; J C Quevedo; C Rodríguez-Lozano
Journal:  Osteoporos Int       Date:  2010-10-06       Impact factor: 4.507

2.  The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed?

Authors:  Elizabeth A Streeten; Asif Mohamed; Amish Gandhi; Denise Orwig; Paul Sack; Robert Sterling; Vincent D Pellegrini
Journal:  J Bone Joint Surg Am       Date:  2006-09       Impact factor: 5.284

3.  Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment.

Authors:  L Boudou; B Gerbay; F Chopin; E Ollagnier; P Collet; T Thomas
Journal:  Osteoporos Int       Date:  2011-04-29       Impact factor: 4.507

Review 4.  Denosumab in osteoporosis.

Authors:  Dima L Diab; Nelson B Watts
Journal:  Expert Opin Drug Saf       Date:  2013-12-02       Impact factor: 4.250

5.  Secondary prevention of osteoporotic fractures--an "OPTIMAL" model of care from Singapore.

Authors:  M Chandran; M Z W Tan; M Cheen; S B Tan; M Leong; T C Lau
Journal:  Osteoporos Int       Date:  2013-04-25       Impact factor: 4.507

6.  Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men.

Authors:  Dana Bliuc; Nguyen D Nguyen; Tuan V Nguyen; John A Eisman; Jacqueline R Center
Journal:  J Bone Miner Res       Date:  2013-11       Impact factor: 6.741

7.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  Optimizing fracture prevention: the fracture liaison service, an observational study.

Authors:  D A Eekman; S H van Helden; A M Huisman; H J J Verhaar; I E M Bultink; P P Geusens; P Lips; W F Lems
Journal:  Osteoporos Int       Date:  2013-09-13       Impact factor: 4.507

9.  Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.

Authors:  D Prieto-Alhambra; A Judge; N K Arden; C Cooper; K W Lyles; M K Javaid
Journal:  Osteoporos Int       Date:  2013-06-28       Impact factor: 4.507

10.  Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle.

Authors:  K Akesson; D Marsh; P J Mitchell; A R McLellan; J Stenmark; D D Pierroz; C Kyer; C Cooper
Journal:  Osteoporos Int       Date:  2013-04-16       Impact factor: 4.507

View more
  12 in total

1.  Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.

Authors:  A Naranjo; S Ojeda-Bruno; A Bilbao-Cantarero; J C Quevedo-Abeledo; B V Diaz-González; C Rodríguez-Lozano
Journal:  Osteoporos Int       Date:  2015-06-06       Impact factor: 4.507

2.  Secondary prevention of osteoporotic fractures: evaluation of the Lille University Hospital's Fracture Liaison Service between January 2016 and January 2018.

Authors:  A Pflimlin; A Gournay; I Delabrière; C Chantelot; F Puisieux; B Cortet; J Paccou
Journal:  Osteoporos Int       Date:  2019-06-05       Impact factor: 4.507

3.  Post-fracture care: do we need to educate patients rather than doctors? The PREVOST randomized controlled trial.

Authors:  B Merle; R Chapurlat; E Vignot; T Thomas; J Haesebaert; A-M Schott
Journal:  Osteoporos Int       Date:  2017-02-28       Impact factor: 4.507

Review 4.  Improving drug adherence in osteoporosis: an update on more recent studies.

Authors:  Ayesha Jaleel; Kenneth G Saag; Maria I Danila
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-07-10       Impact factor: 5.346

5.  Meeting international standards of secondary fracture prevention: a survey on Fracture Liaison Services in the Netherlands.

Authors:  P van den Berg; D H Schweitzer; P M M van Haard; J P van den Bergh; P P Geusens
Journal:  Osteoporos Int       Date:  2015-04-10       Impact factor: 4.507

6.  Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.

Authors:  A Gamboa; E Duaso; P Marimón; M Sandiumenge; E Escalante; C Lumbreras; A Tarrida
Journal:  Osteoporos Int       Date:  2018-08-03       Impact factor: 4.507

7.  Rush Fracture Liaison Service for capturing "missed opportunities" to treat osteoporosis in patients with fragility fractures.

Authors:  M J Gupta; S Shah; S Peterson; S Baim
Journal:  Osteoporos Int       Date:  2018-06-04       Impact factor: 4.507

Review 8.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

9.  Long-term persistence with anti-osteoporosis drugs after fracture.

Authors:  C Klop; P M J Welsing; P J M Elders; J A Overbeek; P C Souverein; A M Burden; H A W van Onzenoort; H G M Leufkens; J W J Bijlsma; F de Vries
Journal:  Osteoporos Int       Date:  2015-03-31       Impact factor: 4.507

10.  The impact of a standardized order set for the management of non-hip fragility fractures in a Fracture Liaison Service.

Authors:  A Senay; J Delisle; M Giroux; G Y Laflamme; S Leduc; M Malo; H Nguyen; P Ranger; J C Fernandes
Journal:  Osteoporos Int       Date:  2016-07-01       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.